Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3404-3411

  Marcucci, Guido ^a   Stock, Wendy ^a   Dai, Guowei ^a   Klisovic, Rebecca B ^a   Liu, Shujun ^a   Klisovic, Marko I ^a   Blum, William ^a   Kefauver, Cheryl ^a   Sher, Dorie A ^a   Green, Margaret ^a   Moran, Mollie ^a   Maharry, Kati ^a   Novick, Steven ^a   Bloomfield, Clara D ^a   Zwiebel, James A ^a   Larson, Richard A ^a   Grever, Michael R ^a   Chan, Kenneth K ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; OBLIMERSEN; PHENYTOIN; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; ASCITES; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GERIATRIC PATIENT; HEART ARRHYTHMIA; HUMAN; HYPOXIA; LUNG INFILTRATE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEIZURE; SIDE EFFECT; SKIN TOXICITY; BIOAVAILABILITY; CANCER STAGING; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROBABILITY; PROGNOSIS; REMISSION; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDES, ANTISENSE; PROBABILITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 20644469046     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.118     Document Type: Article

References (36)

1. Lowenberg B, Griffin JD, Tallman MS: Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program) 82-101, 2003
2. Lowenberg B: Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 14:65-75, 2001
3. Mrozek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
4. Stone RM: The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52:363-371, 2002
5. Sekeres MA, Stone RM: The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 14:24-30, 2002
6. Sekeres MA, Stone R: Older adults with acute myeloid leukemia. Curr Oncol Rep 4:403-409, 2002
7. Sekeres MA, Stone RM, Zahrieh D, et al: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18:809-816, 2004
8. Lichtman MA, Rowe JM: The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 31:185-197, 2004
9. Estey E: Clinical trials in AML of the elderly: Should we change our methodology? Leukemia 18:1772-1774, 2004
10. Andreeff M, Milella M, Carter BZ, et al: Targeted therapy of AML new concepts. Ann Hematol 83:S51-S53, 2004 (suppl 1)
11. Marie JP: Drug resistance in hematologic malignancies. Curr Opin Oncol 13:463-469, 2001
12. Campos L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096, 1993
13. Andreeff M, Konopleva M: Mechanisms of drug resistance in AML. Cancer Treat Res 112:237-262, 2002
14. Banker DE, Radich J, Becker A, et al: The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 4:3051-3062, 1998
15. Del Poeta G, Venditti A, Del Principe MI, et al: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101:2125-2131, 2003
16. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell 3:17-22, 2003
17. Klasa RJ, Gillum AM, Klem RE, et al: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193-213, 2002
18. Marcucci G, Byrd JC, Dai G, et al: Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425-432, 2003
19. Waters JS, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823, 2000
20. Tolcher AW, Kuhn J, Schwartz G, et al: A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10:5048-5057, 2004
21. Morris MJ, Tong WP, Cordon-Cardo C, et al: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679-683, 2002
22. Rudin CM, Kozloff M, Hoffman PC, et al: Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117, 2004
23. Marshall J, Chen H, Yang D, et al: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 15:1274-1283, 2004
24. Chi KN, Gleave ME, Klasa R, et al: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920-3927, 2001
25. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000
26. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
27. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines-American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
28. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
29. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
30. Hattori R, Hernandez TE, Zhu L, et al: An essential role of the antioxidant gene Bcl-2 in myocardial adaptation to ischemia: An insight with antisense Bcl-2 therapy. Antioxid Redox Signal 3:403-413, 2001
31. Dai G, Chan KK, Liu S, et al: Cellular uptake and intracellular levels of the bcl-2 antisense G3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res (in press)
32. Crooke ST: Progress in antisense technology. Annu Rev Med 55:61-95, 2004
33. Stephens AC, Rivers RP: Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther 5:118-122, 2003
34. Konopleva M, Tari AM, Estrov Z, et al: Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95:3929-3938, 2000
35. Bonnefoy-Berard N, Aouacheria A, Verschelde C, et al: Control of proliferation by Bcl-2 family members. Biochim Biophys Acta 1644:159-168, 2004
36. Lai JC, Benimetskaya L, Santella RM, et al: G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther 2:1031-1043, 2003